Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for
stage I to stage IIIA disease, and are< 5% for stage IIIB/IV disease. Improvements have been …

Despite advances in our understanding of the molecular biology of the disease and
improved therapeutics, lung cancer remains the most common cause of cancer-related …

Chemoradiotherapy followed by consolidation durvalumab (CCRT+ D) improves survival in
patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence …

Materials and methods PubMed and EMBASE were searched using the following keywords:
locally advanced non-small cell lung cancer, unresectable non-small cell lung cancer …

Stereotactic body radiation therapy (SBRT) is an effective and well tolerated treatment for
early stage non-small cell lung cancer (NSCLC). The high doses used in thoracic SBRT can …

Radiation-induced immune effects have been extensively deciphered over the last few
years, leading to the concept of the dual immune effect of radiotherapy with both …

Importance Intrathoracic progression remains the predominant pattern of failure in patients
treated with concurrent chemoradiation followed by a consolidation immune checkpoint …

In unresectable stage III non-small cell lung cancer (NSCLC), the standard of care for most fit
patients is concurrent chemotherapy with normofractionated radiotherapy (NFRT), followed …

Purpose We report the safety data from the first multicenter phase 1 trial investigating the
use of hypofractionated proton therapy with concurrent chemotherapy for patients with stage …

Purpose This study prospectively evaluated the efficacy and safety of concurrent chemo-
proton therapy (CCPT) using adaptive planning for unresectable stage III non-small cell lung …